Received:12 February 2023 Revised:22 April 2023Accepted:24 April 2023D0:10.1111/hep.14167NEPHROLOGYREVIEWARTICLEWILEYPractical considerations for the use of SGLT-2 inhibitors in theAsia-Pacific countries-An expert consensus statementAdrian Liew1 Aida Lydia2 Bien J.Matawaran3Paweena Susantitaphong Huong Thi Bich Tran5 Lee Ling Lim6.7.8The Kidney Transplant Practice,MountElizabeth Novena Hospital,Singapore,AbstractSingaporeRecent clinical studies have demonstrated the effectiveness of SGLT-2 inhibitors in2Division of Nephrology and Hypertension.Department of Internal Medicine,Faculty ofreducing the risks of cardiovascular and renal events in both patients with and without typeMedicine Universitas Indonesia-Dr Cipto2 diabetes mellitus.Consequently,many intemational guidelines have begun advocatingMangunkusumo Hospital,Jakarta,Indonesia3Section of Endocrinology.Diabetes andfor the use of SGLT-2 inhibitors for the purpose of organ protection rather than as simply aMetabolism,Department of Medicine,glucose-lowering agent.However,despite the consistent dinical benefits and availableUniversity of Santo Tomas Hospital,Manila,strong guideline recommendations,the utilization of SGLT-2 inhibitors have been unex-PhilippinesDivision of Nephrology.Department ofpectedly low in many countries,a trend which is much more noticeable in low resource set-Medicine,Faculty of Medicine,Chulalongkomtings.Unfamiliarity with the recent focus in their organ protective role and clinicalUniversity.King Chulalongkom MemorialHospital,Bangkok,Thailandindications;concerns with potential adverse effects of SGLT-2 inhibitors,including acuteSRenal Division,Department of Medicine,kidney injury,genitourinary infections,euglycemic ketoacidosis;and their safety profile inUniversity of Medicine and Pharmacy.elderly populations have been identified as deterring factors to their more widespread use.Ho Chi Minh City,VietnamDepartment of Medicine,Faculty ofThis review serves as a practical guide to dinicians managing patients who could benefitMedicine,University of Malaya Kuala Lumpur,from SGLT-2 inhibitors treatment and instill greater confidence in the initiation of theseMalaysiadrugs,with the aim of optimizing their utilization rates in high-risk populations.7Department of Medicineand Therapeutics.The Chinese University of Hong Kong.HongKong.SAR,ChinaKEYWORDSAsia Diabetes Foundation.Hong Kong.SARacute kidney injury,chronic kidney disease,ketosis,sodium-glucose transporter 2 inhibitors,Chinaurinary tract infectionsCorrespondenceSummary at a glanceAdrian Liew,The Kidney Transplant Practice,Mount Elizabeth Novena Hospital,Singapore,This paper provides a summary of indications for SGLT-2 inhibitor therapy inSingapore.appropriate patient populations based on current available clinical evidence.In addi-Email:draliew2@gmail.comtion,it provides an expert consensus on practical suggestions in mitigating the clinicalLee Ling Lim,Department of Medicine,Facultyof Medicine,University of Malaya,Kualaiss
